Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

NCT05256290 is registered in ClinicalTrials.gov with Black Diamond Therapeutics, Inc. as lead sponsor.

NCT NCT05256290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05256290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer
Lead sponsor
Black Diamond Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 31, 2022
Completion date
December 31, 2027
Enrollment
200 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung carcinoma, advanced non-small cell squamous lung cancer, egf-r positive non-small cell lung cancer, egfr-tki resistant mutation, epidermal growth factor receptor c797s, epidermal growth factor receptor g719x, metastatic lung cancer, metastatic lung non-small cell carcinoma, non-small cell lung cancer, nsclc